ECONOMIC PROSPECT ANALYSIS

Eli Lilly and Company (LLY)

Forward-looking competitive assessment — compiled by Gemini 3.1

Strong Prospect

Eli Lilly is the GLP-1 story — Mounjaro and Zepbound address a $100B+ TAM. But the stock prices in perfection at 50x+ earnings, manufacturing is the binding constraint, and competition from Novo Nordisk and emerging oral GLP-1s will intensify.

View DCF Intrinsic Value Analysis →

Competitive Momentum

28/35

Moat Durability

25/35

Sentiment & Catalysts

23/30

🚀 Key Catalysts

Mounjaro/Zepbound combined peak sales exceeding $50B as indications expand
Donanemab gaining broader adoption in Alzheimer's
Oral GLP-1 formulation dramatically expanding addressable patient population

⚠️ Key Risks

Manufacturing capacity failing to meet demand — $20B+ invested but production delays would impact revenue
GLP-1 competition intensifying (Novo Nordisk, Amgen MariTide, Pfizer, Roche)
Insurance coverage pushback at $1,000+/month compressing realized revenue per patient

Methodology

Score is based on three pillars: Competitive Momentum (0-35), Moat Durability (0-35), and Sentiment & Catalysts (0-30), totaling 0-100.

Disclaimer: This economic prospect score is for educational purposes only. It is generated by an AI model (Gemini 3.1) based on publicly available data and may not reflect all material factors. This does not constitute investment advice. Always conduct your own due diligence.